Physician profile
Asante K Mendes
NPI 1114109212
$959.04
in general payments reported to CMS, 2019-2025
12 companies · $179 in 2025
The $179 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $63.38 · 2021: $63.66 · 2022: $301 · 2023: $198 · 2024: $154 · 2025: $179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $531.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $531.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $263.79 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $252.22 | 2023-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Neurocrine Biosciences, INC. | $118.03 | 2022-2025 | Ingrezza |
| Acadia Pharmaceuticals INC | $91.07 | 2022-2023 | Nuplazid |
| Urovant Sciences INC | $48.66 | 2022 | |
| Lundbeck LLC | $40.02 | 2025 | Rexulti |
| Indivior INC. | $35.82 | 2025 | Sublocade |
| Allergan, INC. | $29.99 | 2019 | |
| Ucb, INC. | $25.49 | 2024 | Briviact |
| Braeburn INC. | $22.31 | 2024 | Brixadi |
| Vertical Pharmaceuticals, LLC | $17.18 | 2024 | Relexxii |
| Corium, LLC | $14.46 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asante Mendes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.